Lessons from the PROVE-IT trial. Higher dose of potent statin better for high-risk patients
Kiran K. Khush, MD
Division of Cardiology, Department of Medicine, University of California, San Francisco
David Waters, MD
Division of Cardiology, Department of Medicine, University of California, San Francisco, and San Francisco General Hospital
Address: Kiran K. Khush, MD, Division of Cardiology, Department of Medicine, 505 Parnassus Avenue, Box 0124, San Francisco, CA 94143; e-mail email@example.com
Dr. Waters has indicated that he is on the speakers’ bureau of Pfizer, Merck, and AstraZeneca, and has received grant or research support from AstraZeneca and Merck.
ABSTRACTThe Pravastatin or Atorvastatin Evaluation and Infection Therapy trial (PROVE-IT/TIMI-22) showed that in patients with acute coronary syndromes, aggressive lipid-lowering using atorvastatin 80 mg/day provided greater protection against death or major cardiovascular events than did moderate lipid-lowering using pravastatin 40 mg/day. Lowering the low-density lipoprotein cholesterol level to approximately 62 mg/dL with atorvastatin resulted in a 16% reduction in cardiovascular end points.